Skip to main content
TipRanks
Go Ultimate75% OFF

BrightPath Biotherapeutics Co.Ltd. (4594) Stock Price & Analysis

0 Followers

4594 Stock Chart & Stats

¥39.00¥1.00(2.63%)
At close: 3:30 PM GMT+9
¥40¥50¥60Aug 24Sep 7Sep 18Oct 5Oct 19Nov 2Nov 16
Day’s Range
JPY 37.00 - JPY 39.00
52-Week Range
JPY 36.00 - JPY 96.00
Previous Close
JPY 38.00
Volume
N/A
Average Volume (3M)
1.11M
Market Cap
JPY 5.34B
Enterprise Value
JPY 5.67B
Total Cash (Recent Filing)
JPY 2.16B
Total Debt (Recent Filing)
JPY 0
Price to Earnings (P/E)
―
Beta
0.80
Next Earnings
Feb 05, 2027 (Est.)
EPS Estimate
N/A
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Low Leverage

Very low leverage reduces refinancing pressure and limits mandatory financing costs while the company remains loss-making. This gives BrightPath greater balance-sheet flexibility to continue research activities and manage funding decisions over the next several quarters.

Balance-Sheet Buffer

A sizable asset and equity base relative to the company’s scale provides some capacity to absorb ongoing operating losses. Although it does not resolve cash burn, this buffer can support business continuity and reduce immediate balance-sheet stress during development activities.

Positive Gross Margin

Positive reported gross margin indicates that the company has generated revenue above associated gross costs in the latest periods. This is a constructive operating foundation, even though substantial R&D and other expenses still prevent profitability and self-funded growth.

Bears Say

Revenue Instability

The extreme revenue swing points to weak commercial traction and reliance on uneven milestone or other income rather than a dependable recurring revenue base. Such volatility makes planning difficult and limits confidence that near-term operations can fund development.

Persistent Operating Losses

Large recurring EBIT and net losses show that operating costs, including the company’s development burden, remain far above its revenue base. Continued losses weaken retained equity and make a durable path to profitability uncertain over the next several quarters.

Sustained Cash Burn

Consistently negative operating and free cash flow means BrightPath is not currently self-funding its activities. With no durable improvement trend identified, ongoing burn increases financing dependence and can create dilution or runway pressure if losses continue.

4594 FAQ

What was BrightPath Biotherapeutics Co.Ltd.’s price range in the past 12 months?
BrightPath Biotherapeutics Co.Ltd. lowest stock price was ¥36.00 and its highest was ¥96.00 in the past 12 months.
What is BrightPath Biotherapeutics Co.Ltd.’s market cap?
BrightPath Biotherapeutics Co.Ltd.’s market cap is ¥5.34B.
When is BrightPath Biotherapeutics Co.Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were BrightPath Biotherapeutics Co.Ltd.’s earnings last quarter?
BrightPath Biotherapeutics Co.Ltd. released its earnings results on Nov 13, 2026. The company reported -¥5.569 earnings per share for the quarter.
Is BrightPath Biotherapeutics Co.Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does BrightPath Biotherapeutics Co.Ltd. pay dividends?
BrightPath Biotherapeutics Co.Ltd. does not currently pay dividends.
What is BrightPath Biotherapeutics Co.Ltd.’s EPS estimate?
BrightPath Biotherapeutics Co.Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BrightPath Biotherapeutics Co.Ltd. have?
BrightPath Biotherapeutics Co.Ltd. has 140,515,800 shares outstanding.
What happened to BrightPath Biotherapeutics Co.Ltd.’s price movement after its last earnings report?
BrightPath Biotherapeutics Co.Ltd. reported an EPS of -¥5.569 in its last earnings report. Following the earnings report the stock price went down -2.564%.
Which hedge fund is a major shareholder of BrightPath Biotherapeutics Co.Ltd.?
Currently, no hedge funds are holding shares in JP:4594
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology